A proof-of-concept study found that mice injected with a DNA vaccine based on autologous tumor neoantigens and subsequently pulsed via electroporation, elicited predominantly MHC-I response, inducing CD8+ T cells [95], providing rationale for future use of DNA neoantigen vaccines. Here, CD8A is linked to neoplasm.